SynthesisAnnals of medicine2024
Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy.
Synthesis in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Prognostic value of inflammation-immunity-nutrition score in cancer patients: a meta-analysis.Annals of medicine · 2026Pooled it
- Sarcopenia Affects the Clinical Efficacy of Immune Checkpoint Inhibitors in Gastric Cancer Patients: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors.Annals of medicine · 2025Pooled it
- Albumin-globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients.Annals of medicine · 2025Pooled it
- Prognostic significance of prognostic nutritional index in patients with head and neck squamous cell carcinoma.Frontiers in immunology · 2025Pooled it
- The predictive value of the neutrophil/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma.Frontiers in immunology · 2025Pooled it
- Lymphocyte-to-C-reactive protein ratio as a clinically feasible nutrition-inflammation marker for predicting outcomes in patients with gastric cancer.Oncology letters · 2026Article
- Prognostic value of the preoperative lactate dehydrogenase-to-albumin ratio in patients with gastrointestinal cancer.Oncology letters · 2026Article
- Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy.Journal of clinical medicine · 2026Article
- Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.Scientific reports · 2026Article
- Development and validation of a clinical-adipometric nomogram for predicting tumor response to transarterial chemoembolization in hepatocellular carcinoma.Scientific reports · 2026Article
- Changes in nutritional status in hepatocellular carcinoma patients treated with sorafenib.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Baseline (modified) Glasgow prognostic score as a predictor of therapeutic response to immune checkpoint inhibitors in solid tumors: A systematic review and meta‑analysis.Oncology letters · 2025Article
- Prognostic value of the lactate dehydrogenase to albumin ratio in cancer patients.Frontiers in nutrition · 2025Article
- Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to examine the possible relationship between body composition parameters, sarcopenia, and clinical outcomes in hepatocellular carcinoma (HCC) patients who received immune checkpoint inhibitor (ICI) treatment.
methodsThree online databases, including Embase, PubMed, and the Cochrane Library, were thoroughly searched for literature describing the relationship between body composition parameters, sarcopenia, and outcomes of ICI-treated HCC patients from the start of each database to 21 January 2024. The Newcastle-Ottawa Scale was used to rate the quality of the studies. The assessed outcomes included hazard ratio (HR) for OS and PFS, as well as odds ratio (OR) for ORR and DCR.
resultsThis analysis included a total of 15 articles with a combined patient cohort of 1543 individuals. The results demonstrated that HCC patients with low skeletal muscle index (SMI) had significantly inferior OS (HR: 1.68,
conclusionThe presence of sarcopenia and low SMI in HCC patients undergoing treatment with ICIs was found to be related to inferior treatment response and reduced long-term effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.